Monday, August 31, 2026

Moderna Stock Bullish Momentum With A 4.7% Jump On Friday

ViaNews Editorial Team

November 20, 2020

Moderna Stock Bullish Momentum With A 4.7% Jump On Friday

According to today's article on Bloomberg Quint, "EU Could Approve BioNTech, Moderna Vaccines in December."

Shares of Moderna rose 4.7% to $97.13 at 12:05 EST on Friday, after one succeed sessions in a rows of gains. The Nasdaq Stock Market is rising 0.22% to $11931, after one succeed sessions in a rows of gains, on what seems, at the moment, a somewhat positive trend trading session on The Nasdaq Stock Market.

According to yesterday's article on Bloomberg Quint, "Moderna Vaccine Production Is Gearing Up, Partner Lonza Says."

Moderna's last close was $92.77, below its 52-week high of $103.2.

Moderna's sales growth is 1216.8% for the ongoing quarter and 2299% for the next. The company's growth estimates for the present quarter is a negative 67.6% and positive 142.9% for the next.

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Moderna's stock is valued at $97.13 at 12:05 EST, below its 52-week high of $103.2 and way higher than its 52-week low of $17.68.

Moderna's value is way above its 50-day moving average of $75.37 and way higher than its 200-day moving average of $68.93.

Moderna vaccine found highly effective at preventing covid. According to Bloomberg Quint on Mon Nov 16, "Moderna shares rised more than 9% in pre-market U.S."

According to MarketWatch on Mon Nov 16, "Stock futures surge as Moderna says coronavirus vaccine is 94.5% effective in trial."

Moderna shares soar premarket after coronavirus vaccine candidate achieves 94.5% efficacy in phase 3 trial. According to MarketWatch on Mon Nov 16, "Moderna Inc"

Update: Moderna shares soar premarket after coronavirus vaccine candidate achieves 94.5% efficacy in phase 3 trial. According to MarketWatch on Mon Nov 16, "Moderna Inc"

According to MarketWatch on Mon Nov 16, "Moderna shares have surged 18% in premarket on coronavirus vaccine trial data."

Stocks making the biggest moves in the premarket: Moderna, casper sleep, Uber, tapestry & more. According to CNBC on Mon Nov 16, "The stocks making the biggest moves in premarket trading include Moderna, Casper Sleep, Uber, Tapestry, and more.."

According to Bloomberg Quint on Mon Nov 16, "NYC-Linked Stocks Climb on Optimism Over Moderna Vaccine Results."

Stocks making the biggest moves midday: Moderna, simon property, bbva, virgin galactic & more. According to CNBC on Mon Nov 16, "Moderna gets a boost from positive vaccine trial data."

According to Bloomberg Quint on Mon Nov 16, "European Stocks Surge to February High on Moderna Vaccine Study."

According to Bloomberg Quint on Mon Nov 16, "Moderna Adds to Vaccine Hope; New California Curbs: Virus Update."

According to Bloomberg Quint on Tue Nov 17, "Moderna Vaccine Offers Possible Antidote to Deep-Freeze Problem."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI's Trust Gap: Microsoft-Mistral Ecosystem Expansion Meets a Governance Deficit in Agentic Adoption
Microsoft is deepening its AI platform bet through simultaneous moves — expanding its Mistral partnership (Copilot Studio, Foundry, European infrastructure capacity) and deepening enterprise AI governance ties with Manulife — just as independent research (Google Cloud, VentureBeat, Box) shows enterprises racing toward agentic AI adoption (100% planned within two years) while data access and trust in agent decisions lag badly (average 45% data access, only ~half trust agent outputs). The result is a structural mismatch between platform-vendor momentum and enterprise readiness to actually govern and trust the agents being deployed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
Same entity (Morgan Stanley & Co. LLC), same metric (net_income), same fiscal period (Q1 2026), same observation date (2026-03-31), but vastly different values: $5.567 billion vs. $5.57. These cannot coexist for the same time period. Fact B appears to be a data entry error (possible missing decimal placement: 5.57 should likely be 5,567,000,000 or a per-share figure incorrectly entered as total).
We flag conflicts openly ›
Recently verified
Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,257 source documents archived
Query this data → isubstrate.com